FDA approves REBLOZYL ® for treatment of beta thalassemia
-
Last Update: 2020-06-07
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
today, Celgene and Acceleron Pharma announced that the U.SFood anddrug(http://Regulatory Authority (
FDA(http://) has approved THE use of REBLOZY®PT-aamt for the treatment of beta thalassemiaREBLOZYL is not a complete substitute for RBC blood transfusion therapy, but it is the first and only FDA-approved red blood cell maturation agent.This is a new treatment that promotes cell maturation by regulating advanced red blood cells to help patients reduce the burden of red blood cell transfusionREBLOZYL reached primary and secondary endpoints by approving theassessment of itstest(http:// in clinical 3 randomized, double-blind, placebo-controlled, multicenterREBLOZYL is the first and only FDA-approved carotenoid mature agent, and the first FDA-approved(http://drug for beta thalassemia
treatment
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
